Form 6-K XTL BIOPHARMACEUTICALS For: Sep 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
XTL Biopharma (XTLB) Reports Breakeven Q2 Loss
September 1, 2015 9:20 AM EDTXTL Biopharma (NASDAQ: XTLB) reported Q2 loss of $0.00, versus $0.00 reported last year.
Following XTL's registered direct offering in April, 2015, XTL had US$4.8 million in cash and cash equivalents as of June 30, 2015.
For earnings history and earnings-related data on XTL Biopharma (XTLB) click here.
... More